Abstract
Abstract Renal oncocytomas are benign tumors that consist of a large population of well- differentiated neoplastic cells arising from the intercalated cells of the collecting duct. They account for approximately 3-7% of all renal tumors. As most oncocytomas are single and unilateral, the standard management is surgical excision. However, 2-12% are multifocal and 4-12% are bilateral. If the oncocytomas are bilateral and grow large enough to impair kidney function, these patients may require hemodialysis. Given the rarity of bilateral oncocytomas, there is scarce data discussing non-surgical treatment regimens for these patients. There are no large studies analyzing systemic therapy for oncocytomas and literature search has yielded no case reports on this topic. We report a case in which pazopanib was used to decrease the size of multifocal oncocytomas. Given the clinical success in this patient, pazopanib could be considered for disease control and renal preservation for patients with bilateral oncocytomas.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
